Replies to post #592216 on NorthWest Biotherapeutics Inc (NWBO)

[Jarheef]

Excellent point I like that perspective!

[FeMike]

Commercial approval has zero impact on specials revenue. It wasnt/isn’t the bottleneck. That it just happened is irrelevant.

Revenue doubling maybe means they went from 2-3 patients in Q1 2022 to 3-5 patients in 2023. So no, there was no change. That is noise. People here are trying to claim we’ll see double digit units monthly prior to approval. It’s not happening.

[FeMike]

More than double last year, same time and the commercial approval just came, the publication just last November. It’s clearly scaling up and will likely continue to do so.

Clearly

[exwannabe]

More than double last year, same time and the commercial approval just came, the publication just last November.

BS. This Q was $201k. Q2 of 2022 was $477k So it fell by over 50% Q over Q. Also fell sequentially from Q1 of 23 by over 70%

Further, it is still produced under Specials so the MIA has no impact.